Skip to main content
Premium Trial:

Request an Annual Quote

Gain Therapeutics Nabs $2.8M Grant for GBA1 Parkinson's Disease Drug Candidate

NEW YORK – Biotechnology company Gain Therapeutics on Wednesday said it has received a CHF 2.5 million ($2.8 million) grant from an innovation accelerator to develop GT-02287 as a treatment for slowing or halting the progression of Parkinson's disease associated with GBA1 gene mutations.

The funding comes from Swiss Accelerator, an effort supported by Innosuisse, also known as the Swiss Innovation Agency, which funds industry-led scientific advances that may benefit society in Switzerland. The grant awarded to Gain Therapeutics is one of 53 projects the accelerator has chosen to fund following a call for proposals last year. The grants cover up to 70 percent of the costs for each project.

Gain Therapeutics will use the funds to support clinical pharmacology and preclinical studies for GT-02287, a small molecule modulator that restores enzyme function for beta-glucocerebrosidase (GCase), which is expressed by the GBA1 gene. The drug is designed to target and bind to GCase, allowing it to fold correctly and preventing accumulation of alpha-synuclein, a hallmark of Parkinson's disease. The company will conduct the grant-funded research as GT-02287 progresses through Phase I and II clinical trials.

"This funding provides significant financial support for the further development of GT-02287 as we remain on track to submit the dossier for the start of the Phase I clinical study in mid-2023," Gain Therapeutics CEO Matthias Alder said in a statement.

This is the second grant Gain Therapeutics has received from Innosuisse. In 2021, Innosuisse awarded the firm CHF 1.5 million in funding to research allosteric modulators for GBA1-related diseases.